Catalyst Event
SK Biopharmaceuticals Co Ltd (326030) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
5/29/2026, 12:00:00 AM
SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.
Korean Translation
2026년 5월 12일 발표에 따라 2026년 5월 29일 장 마감 후 SK바이오팜의 MSCI 한국 지수 편출이 예정됨. 지수 편출에 따른 패시브 자금 유출로 중간 수준의 주가 영향이 예상됨.
Related Recent Events
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Lirafugratinib as a second-line treatment for bile duct cancer, which was granted priority review and carries an estimated >10% price impact, scheduled.
9/27/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer, following a 'Class 2' resubmission in January 2026 and carrying an estimated >10% price impact, scheduled.
7/23/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM
ANTA Sports Products Limited (2020) · Other
Adjustment to the conversion price of EUR 1.5 billion convertible bonds from HK$101.13 to HK$99.80 effective May 19, 2026; technical adjustment with minimal price impact expected, scheduled.
5/19/2026, 12:00:00 AM